<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31271" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Von Willebrand Factor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cortes</surname>
            <given-names>Gillean A.</given-names>
          </name>
          <aff>A.T. Still University School of Osteopathic Medicine in Arizona</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moore</surname>
            <given-names>Marlyn J.</given-names>
          </name>
          <aff>Uniformed Services University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>El-Nakeep</surname>
            <given-names>Sarah</given-names>
          </name>
          <aff>Gastroentrology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gillean Cortes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marlyn Moore declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah El-Nakeep declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31271.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Von Willebrand factor (vWF) is a glycoprotein crucial to primary hemostasis through platelet and subendothelial collagen adhesion and the intrinsic coagulation cascade through factor VIII stabilization. It resides in the plasma, subendothelial matrix, and storage granules within endothelial cells and platelets.<xref ref-type="bibr" rid="article-31271.r1">[1]</xref>&#x000a0;vWF is a multimer composed of repeating subunits that create several binding sites for the proteins with which it interacts.<xref ref-type="bibr" rid="article-31271.r2">[2]</xref>&#x000a0;VWF is named after the physician Erik von Willebrand, who first identified and described a bleeding disorder later attributed to insufficient quantity or dysfunctional quality of this glycoprotein.<xref ref-type="bibr" rid="article-31271.r3">[3]</xref>&#x000a0;Diagnoses of importance related to vWF include von Willebrand disease (vWD), thrombotic thrombocytopenic purpura (TTP), and Bernard-Soulier syndrome.<xref ref-type="bibr" rid="article-31271.r4">[4]</xref><xref ref-type="bibr" rid="article-31271.r5">[5]</xref></p>
      </sec>
      <sec id="article-31271.s2" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>The initial synthesis of vWF, transcribed from chromosome 12, occurs in endothelial cells and megakaryocytes as a 2813 amino acid pre-pro-polypeptide of repeating domain sequences. The first 22 amino serve as a signal peptide to initiate post-translational processing.<xref ref-type="bibr" rid="article-31271.r6">[6]</xref>&#x000a0;The signal peptide is then cleaved to allow the pro-peptide monomers to dimerize.<xref ref-type="bibr" rid="article-31271.r7">[7]</xref>&#x000a0;Von Willebrand factor&#x000a0;is rich in cysteine, a neutral yet polar amino acid, to facilitate multimerization and disulfide bridging necessary for its higher-order structure. Multimerization can combine different amounts of pro-vWF subunits, resulting in a heterogeneous mix of multimers ranging from as few as&#x000a0;2 to as many as 60 or more pro-vWF subunits. Post-translational glycosylation, sialylation, sulfation, and folding occur in the endoplasmic reticulum and Golgi apparatus. Once assembled, the pro-peptide domains (D1-D2, 741 amino acids), essential to aligning pro-vWF dimers, are cleaved to form the mature 2050 amino acid wWF. Once complete, vWF is transported for storage in alpha-granules of megakaryocytes and platelets and packaged into Weibel-Palade bodies (WPBs) within endothelial cells.<xref ref-type="bibr" rid="article-31271.r1">[1]</xref></p>
      </sec>
      <sec id="article-31271.s3" sec-type="Function">
        <title>Function</title>
        <p>The&#x000a0;2 main functions of vWF in hemostasis include platelet adhesion and Factor VIII stabilization. During primary hemostasis, vascular injury exposes vWF-bound to subendothelial collagen. Then, glycoprotein 1b (GP1b) receptors on the surface of nearby platelets adhere to the exposed vWF, triggering platelet activation and a cascade of events, which includes the release of platelet storage granule content such as vWF from alpha granules and the recruitment of more platelets to form a plug at the site of damaged endothelium.<xref ref-type="bibr" rid="article-31271.r7">[7]</xref>&#x000a0;</p>
        <p>Plasma vWF supports the intrinsic coagulation cascade by stabilizing factor VIII, increasing its circulating half-life. During the intrinsic coagulation pathway, thrombin cleaves the factor VIII binding site with vWF, allowing the release (activation) of factor VIIIa to continue the clotting process.<xref ref-type="bibr" rid="article-31271.r6">[6]</xref>&#x000a0;By serving as a carrier for factor VIII, vWF influences the common coagulation pathway and the generation of thrombin and fibrin.<xref ref-type="bibr" rid="article-31271.r8">[8]</xref>&#x000a0;Without vWF, or more specifically, without the D&#x02019;D3 domains that facilitate vWF and factor VIII binding, factor VIII is rapidly cleared from the circulation, hence the clinical similarities between some forms of vWD and hemophilia A.<xref ref-type="bibr" rid="article-31271.r9">[9]</xref></p>
      </sec>
      <sec id="article-31271.s4" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>VWF multimers have repeating domain sequences with specific functions for each domain. Large vWF multimers, by nature of having more sites for adhesion, are more effective during hemostasis than the smaller varieties with less binding capacity.<xref ref-type="bibr" rid="article-31271.r6">[6]</xref>&#x000a0;The generally acknowledged domain structure is arranged SP-D1-D2-D&#x02019;-D3-A1-A2-A3-D4-C1-C6-CK.<xref ref-type="bibr" rid="article-31271.r1">[1]</xref><xref ref-type="bibr" rid="article-31271.r10">[10]</xref>&#x000a0;Each domain has multiple roles; however, the key functions of the domains are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>SP is the signal peptide that initiates post-translational processing</p>
          </list-item>
          <list-item>
            <p>D1 and D2 are the vWF propeptide domains that interact with D&#x02019; to allow proper alignment during vWF dimerization.</p>
          </list-item>
          <list-item>
            <p>D&#x02019; and D3 interact with D1 and D2 during dimerization and interdimeric cross-linking, p-selectin on the surface of platelets and endothelial cells, and factor VIII within WBP and the circulation.<xref ref-type="bibr" rid="article-31271.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>The A1 domain binds GP1b on platelets and collagen in the subendothelial matrix, as well as several other proteins, such as histones, heparin, osteoprotegerin, and beta-2 integrin receptors on leukocytes.</p>
          </list-item>
          <list-item>
            <p>A2 domain is crucial in regulating vWF activity; the mechanosensitive switch unfolds when exposed to shear stress to expose other vWF binding domains. A2 is also the cleavage site for the zinc protease ADAMTS13, which regulates the size and pro-thrombotic activity of vWF.<xref ref-type="bibr" rid="article-31271.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>A3 domain binds extracellular matrix collagens.</p>
          </list-item>
          <list-item>
            <p>C domains bind with fibrin plasma complement proteins and interact with GPIIb/IIIa during platelet adhesion.<xref ref-type="bibr" rid="article-31271.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>CK (cysteine knot) domain is important for multimerization and post-translational folding.<xref ref-type="bibr" rid="article-31271.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Platelet activation stimulates alpha granules to release vWF to facilitate hemostasis, while endothelial cells utilize a mixture of basal secretion and induced release. In response to vascular injury, WPB undergoes exocytosis, and vWF multimers exposed to shear stress unfold at the A2 domain. Unfolded vWF multimers form long bundles that anchor to subendothelial collagen and expose binding sites for nearby platelets. The A1 domain of vWF interacts with platelet GP1b receptors to initiate platelet aggregation and activation, which leads to alpha granule content release.<xref ref-type="bibr" rid="article-31271.r1">[1]</xref>&#x000a0;In addition to releasing more vWF for further platelet aggregation and fibrin mesh formation, alpha granules also release a protein called thrombospondin-1, which binds to the A2-A3 domains of vWF and competitively inhibits cleavage of vWF by ADAMTS13.<xref ref-type="bibr" rid="article-31271.r12">[12]</xref>&#x000a0;As mentioned, larger vWF multimers are more effective in thrombus formation; therefore, ADAMTS13 is critical to preventing unregulated pro-thrombotic activity.<xref ref-type="bibr" rid="article-31271.r6">[6]</xref></p>
        <p>Plasma vWF is a molecular carrier and binds with factor VIII at its D&#x02019;D3 domains. This prolongs the half-life of factor VIII, making it more readily available to participate in the intrinsic coagulation cascade. Clearance of vWF complexes is multifactorial and varies between individuals based on age, weight, and blood type. It occurs through endothelial cells, hepatocytes, and macrophages in the liver and spleen binding and internalizing the vWf complex, thereby removing it from the circulation.<xref ref-type="bibr" rid="article-31271.r1">[1]</xref><xref ref-type="bibr" rid="article-31271.r9">[9]</xref></p>
      </sec>
      <sec id="article-31271.s5" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>Disorders involving vWF can present on a spectrum of severity, described in more detail below. Relevant testing to assess the specific defect or degree of deficiency can further delineate qualitative versus qualitative platelet or coagulation disorders.<xref ref-type="bibr" rid="article-31271.r13">[13]</xref></p>
        <p>
<bold>Complete blood count</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Platelet count</p>
          </list-item>
          <list-item>
            <p>Red blood cell count</p>
          </list-item>
          <list-item>
            <p>Peripheral smear</p>
          </list-item>
        </list>
        <p>
<bold>Bleeding time</bold>
</p>
        <p>
<bold>Coagulation tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prothrombin time (PT/INR)</p>
          </list-item>
          <list-item>
            <p>Partial thromboplastin time (PTT)</p>
          </list-item>
        </list>
        <p><bold>vWF assays</bold> (quantity and activity)</p>
        <list list-type="bullet">
          <list-item>
            <p>vWF antigen</p>
          </list-item>
          <list-item>
            <p>vWF-collagen-binding</p>
          </list-item>
          <list-item>
            <p>vWF-ristocetin cofactor activity</p>
          </list-item>
          <list-item>
            <p>vWF-factor VIII binding</p>
          </list-item>
          <list-item>
            <p>vWF genotyping</p>
          </list-item>
        </list>
        <p><bold>Factor VIII assays</bold> (quantity and activity)</p>
        <p><bold>ADAMTS13 assays</bold> (quantity and activity)&#x000a0;<xref ref-type="bibr" rid="article-31271.r14">[14]</xref><xref ref-type="bibr" rid="article-31271.r10">[10]</xref></p>
      </sec>
      <sec id="article-31271.s6" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Because vWF is a large, complex, heavily modified glycoprotein with more than&#x000a0;1 role in hemostasis, disorders involving defective or deficient vWF can present&#x000a0;with a spectrum of severity. The most common genetic bleeding disorder, vWD, encompasses&#x000a0;4 subtypes inherited in an autosomal dominant pattern.<xref ref-type="bibr" rid="article-31271.r10">[10]</xref><xref ref-type="bibr" rid="article-31271.r6">[6]</xref>&#x000a0;Clinical presentation includes a family history of a bleeding disorder, easy bruising, gum bleeding, heavy menses, prolonged bleeding after minor trauma, excess bleeding after major trauma, and symptoms of anemia such as fatigue.&#x000a0;</p>
        <p><bold>Type 1 vWD</bold>&#x000a0;is the most common, representing about 80% of cases. It is caused by a decreased quantity of otherwise normal functioning vWF from missense mutations or null alleles. Type 1 vWD is considered the most mild, and the main symptom is mucocutaneous bleeding, which&#x000a0;is exacerbated by taking non-steroidal anti-inflammatory drugs.</p>
        <p><bold>Type 2 vWD&#x000a0;</bold>can be either autosomal dominant or autosomal recessive in its inheritance pattern. It is due to a vWF functional defect and is further subdivided into type IIA, IIB, IIM, and IIN.</p>
        <list list-type="bullet">
          <list-item>
            <p>Type IIA vWD - decreased vWF-platelet binding due to loss of high molecular weight vWF multimers</p>
          </list-item>
          <list-item>
            <p>Type IIB vWD - abnormal vWF A1 domain causing increased vWF-platelet affinity</p>
          </list-item>
          <list-item>
            <p>Type IIM - decreased vWF-platelet binding activity despite normal amounts of high molecular weight vWF multimers</p>
          </list-item>
          <list-item>
            <p>Type IIN - decreased vWF-factor VIII binding due to defective vWF D&#x02019; domain</p>
          </list-item>
        </list>
        <p><bold>Type 3 vWD</bold>&#x000a0;is the most severe, caused by the complete absence of vWF, and follows an autosomal recessive inheritance pattern.<xref ref-type="bibr" rid="article-31271.r15">[15]</xref><xref ref-type="bibr" rid="article-31271.r9">[9]</xref><xref ref-type="bibr" rid="article-31271.r6">[6]</xref></p>
        <p>Lab findings include decreased vWF, normal platelet count, increased bleeding time, normal prothrombin time, and normal or decreased factor VIII corresponding with normal or increased partial thromboplastin time, depending on which domain is affected.<xref ref-type="bibr" rid="article-31271.r15">[15]</xref>&#x000a0;One specific lab test to assess vWF-platelet binding is the ristocetin cofactor assay. Ristocetin cofactor binds to both vWF and platelets, inducing the A1 domain of vWF to bind Gp1b surface receptors on platelets, leading to platelet aggregation. In patients with vWD, agglutination is decreased with ristocetin cofactor assay except for type IIB vWD.<xref ref-type="bibr" rid="article-31271.r6">[6]</xref>&#x000a0;Treatment options for vWD are primarily replacement therapy such as vWF and factor VIII plasma concentrates and recombinant vWF. Desmopressin may also treat insufficient vWF quantity by stimulating the release of endothelial vWF from WPBs.<xref ref-type="bibr" rid="article-31271.r10">[10]</xref></p>
      </sec>
      <sec id="article-31271.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p><bold>TTP</bold>, a rare form&#x000a0;of thrombotic microangiopathy, is caused by defective or deficient ADAMTS13, a vWF-cleaving plasma protease. Mutations in the ADAMTS13 gene (congenital TTP, autosomal recessive) or aberrant autoimmune activity (acquired TTP or immune TTP) can impede enzymatic function such that large vWF multimers accumulate and dramatically increase thrombus formation and platelet consumption.<xref ref-type="bibr" rid="article-31271.r5">[5]</xref><xref ref-type="bibr" rid="article-31271.r16">[16]</xref>&#x000a0;Acquired TTP does not have a single inciting cause but has been associated with pregnancy, HIV, malignancy, lupus, certain medications, and infectious processes.<xref ref-type="bibr" rid="article-31271.r17">[17]</xref><xref ref-type="bibr" rid="article-31271.r12">[12]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical presentation is often described as a triad of neurologic symptoms due to impaired cerebral blood flow, thrombocytopenia, and microangiopathic hemolytic anemia or a pentad of the aforementioned triad plus fever and renal problems. Given its namesake, skin findings such as petechiae and purpura also manifest TTP. Ultimately, microthrombi formed due to this condition can affect the perfusion of any organ system, so the scope of possible symptoms is broad.</p>
          </list-item>
          <list-item>
            <p>Lab findings include low levels of ADAMTS13 activity, antibodies against ADAMTS13 (specific to acquired TTP, not found in congenital TTP), evidence of hemolytic anemia such as elevated lactate dehydrogenase, elevated reticulocyte count, elevated unconjugated bilirubin, and decreased haptoglobin, in addition to the presence of schistocytes, significantly decreased platelet count and increased bleeding time.<xref ref-type="bibr" rid="article-31271.r18">[18]</xref>&#x000a0;Bleeding time is increased in TTP because platelets are consumed in microvascular thrombus formation faster than they are produced, and primary hemostasis depends on the formation of a platelet plug.</p>
          </list-item>
          <list-item>
            <p>Standard treatment for TTP is plasmapheresis and steroids; however, in cases of acquired TTP, rituximab prevents relapse when ADAMTS13 activity levels are especially low by inhibiting the production of ADAMTS13 autoantibodies.<xref ref-type="bibr" rid="article-31271.r16">[16]</xref><xref ref-type="bibr" rid="article-31271.r19">[19]</xref>]</p>
          </list-item>
        </list>
        <p><bold>Bernard-Soulier syndrome</bold>, a rare genetic platelet disorder with an autosomal recessive inheritance pattern, is caused by abnormally large platelets with impaired surface expression of Gp1b, which causes defective platelet adhesion to vWF.</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical presentation typically includes excessive bleeding, epistaxis, easy bruising, petechiae, and (in females) heavy menses.</p>
          </list-item>
          <list-item>
            <p>Lab findings include normal or decreased platelet counts, increased platelet size, increased bleeding time, normal prothrombin time, normal partial thromboplastin time, and a failure of platelet aggregation when exposed to ristocetin cofactor due to Gp1b deficiency.</p>
          </list-item>
          <list-item>
            <p>Treatment for Bernard-Soulier syndrome is supportive, and genetic counseling is recommended. In some scenarios, antifibrinolytic therapy may be administered to reduce post-procedural bleeding.<xref ref-type="bibr" rid="article-31271.r20">[20]</xref></p>
          </list-item>
        </list>
        <p><bold>Coronavirus disease 2019 (COVID-19)</bold> is associated with hypercoagulability; the risk of microthrombosis correlates with disease severity. One proposed mechanism is a quantitative imbalance between vWF and ADAMTS13 activity. Similar to the hypercoagulable state of patients with sepsis, inflammatory microthrombogenesis in severe COVID-19 is facilitated by excessive release of vWF, which outpaces ADAMTS13 activity.<xref ref-type="bibr" rid="article-31271.r5">[5]</xref></p>
      </sec>
      <sec id="article-31271.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31271&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31271">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31271/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31271">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31271.s9">
        <title>References</title>
        <ref id="article-31271.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenting</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Christophe</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Denis</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Mar</month>
            <day>26</day>
            <volume>125</volume>
            <issue>13</issue>
            <fpage>2019</fpage>
            <page-range>2019-28</page-range>
            <pub-id pub-id-type="pmid">25712991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garagiola</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baronciani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Role of von Willebrand factor in the haemostasis.</article-title>
            <source>Blood Transfus</source>
            <year>2011</year>
            <month>May</month>
            <volume>9 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>s3</fpage>
            <page-range>s3-8</page-range>
            <pub-id pub-id-type="pmid">21839029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bharati</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Prashanth</surname>
                <given-names>UR</given-names>
              </name>
            </person-group>
            <article-title>Von Willebrand disease: an overview.</article-title>
            <source>Indian J Pharm Sci</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-16</page-range>
            <pub-id pub-id-type="pmid">22131616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aliotta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bertaggia Calderara</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zermatten</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alberio</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Thrombocytopathies: Not Just Aggregation Defects-The Clinical Relevance of Procoagulant Platelets.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Feb</month>
            <day>24</day>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">33668091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baronciani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Artoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colpani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biganzoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Novembrino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boscolo Anzoletti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Zan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pagliari</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Gualtierotti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aliberti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Panigada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grasselli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blasi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The ADAMTS13-von Willebrand factor axis in COVID-19 patients.</article-title>
            <source>J Thromb Haemost</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>513</fpage>
            <page-range>513-521</page-range>
            <pub-id pub-id-type="pmid">33230904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassan</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of von Willebrand factor.</article-title>
            <source>Blood Coagul Fibrinolysis</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-22</page-range>
            <pub-id pub-id-type="pmid">22089939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lancellotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Cristofaro</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mechanochemistry of von Willebrand factor.</article-title>
            <source>Biomol Concepts</source>
            <year>2019</year>
            <month>Nov</month>
            <day>27</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>194</fpage>
            <page-range>194-208</page-range>
            <pub-id pub-id-type="pmid">31778361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terraube</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>PV</given-names>
              </name>
            </person-group>
            <article-title>Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance.</article-title>
            <source>Haemophilia</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">19473409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pipe</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Lenting</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lillicrap</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Oct</month>
            <day>20</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>2007</fpage>
            <page-range>2007-2016</page-range>
            <pub-id pub-id-type="pmid">27587878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Itzhar-Baikian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boisseau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Veyradier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Updated overview on von Willebrand disease: focus on the interest of genotyping.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>1023</fpage>
            <page-range>1023-1036</page-range>
            <pub-id pub-id-type="pmid">31536379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Randi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>von Willebrand factor regulation of blood vessel formation.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Jul</month>
            <day>12</day>
            <volume>132</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-140</page-range>
            <pub-id pub-id-type="pmid">29866817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Inflammation, von Willebrand factor, and ADAMTS13.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Jul</month>
            <day>12</day>
            <volume>132</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-147</page-range>
            <pub-id pub-id-type="pmid">29866815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Laboratory diagnosis of bleeding disorders. Basic screening tests.</article-title>
            <source>Postgrad Med</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>8</issue>
            <fpage>137</fpage>
            <page-range>137-42, 147-8</page-range>
            <pub-id pub-id-type="pmid">6334288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanby</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>XL</given-names>
              </name>
            </person-group>
            <article-title>Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura.</article-title>
            <source>Hereditary Genet</source>
            <year>2014</year>
            <volume>3</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">25343060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leebeek</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Eikenboom</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Von Willebrand's Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>24</day>
            <volume>375</volume>
            <issue>21</issue>
            <fpage>2067</fpage>
            <page-range>2067-2080</page-range>
            <pub-id pub-id-type="pmid">27959741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joly</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Veyradier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>383</fpage>
            <page-range>383-395</page-range>
            <pub-id pub-id-type="pmid">31107120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Said</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lerma</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic thrombocytopenic purpura.</article-title>
            <source>Dis Mon</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>60</volume>
            <issue>10</issue>
            <fpage>500</fpage>
            <page-range>500-4</page-range>
            <pub-id pub-id-type="pmid">25278278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liesner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Machin</surname>
                <given-names>SJ</given-names>
              </name>
              <collab>British Committee for Standards in Haematology</collab>
            </person-group>
            <article-title>Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.</article-title>
            <source>Br J Haematol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>158</volume>
            <issue>3</issue>
            <fpage>323</fpage>
            <page-range>323-35</page-range>
            <pub-id pub-id-type="pmid">22624596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Qing</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura.</article-title>
            <source>J Int Med Res</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>1253</fpage>
            <page-range>1253-1260</page-range>
            <pub-id pub-id-type="pmid">28639502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31271.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrews</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Berndt</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Bernard-Soulier syndrome: an update.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>656</fpage>
            <page-range>656-62</page-range>
            <pub-id pub-id-type="pmid">23929303</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
